Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer

M. Bontenbal, M. Andersson, J. Wildiers, G. Cocconi, J. Jassem, R. Paridaens, N. Rotmensz, R. Sylvester, H. T. Mouridsen, J. G M Klijn, A. T. Van Oosterom

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The EORTC Breast Cancer Cooperative Group carried out a randomized trial to compare doxorubicin with epirubicin as second-line chemotherapy in patients with metastatic breast cancer. Two hundred and fifty-nine patients with at least one site of metastatic disease entered this trial, of whom 232 patients were eligible. Treatment consisted of doxorubicin 75 mg m-2 or epirubicin 90 mg m-2 i.v. every 3 weeks. The overall response rates for doxorubicin and epirubicin were 36% and 28% respectively (P = 0.173). The median time to progression was 23 weeks for doxorubicin and 19 weeks for epirubicin (P = 0.063) and the median duration of response was 40 weeks for doxorubicin and 32 weeks for epirubicin (P = 0.059). The median survival was 47 weeks for doxorubicin and 44 weeks for epirubicin (P = 0.196). Leucocyte count on retreatment day (P = 0.011) and platelet nadir (P = 0.031) were significantly lower in the doxorubicin-treated group. Also mucositis (P <0.001), diarrhoea (P = 0.005) and haemorrhage (P = 0.048) were significantly worse in the doxorubicin arm. Nine patients on doxorubicin and two patients on epirubicin experienced congestive heart failure (CHF). At the dose levels used in this study, no statistical differences in response rate and survival were found between the two treatment arms. Treatment with doxorubicin tended to result in a slightly longer duration of response and time to progression but doxorubicin was more toxic than epirubicin.

Original languageEnglish
Pages (from-to)2257-2263
Number of pages7
JournalBritish Journal of Cancer
Volume77
Issue number12
Publication statusPublished - 1998

Fingerprint

Epirubicin
Doxorubicin
Breast Neoplasms
Mucositis
Retreatment
Poisons
Leukocyte Count
Reaction Time
Diarrhea
Therapeutics
Blood Platelets
Survival Rate
Heart Failure
Hemorrhage

Keywords

  • Doxorubicin
  • Epirubicin
  • Metastatic breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bontenbal, M., Andersson, M., Wildiers, J., Cocconi, G., Jassem, J., Paridaens, R., ... Van Oosterom, A. T. (1998). Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. British Journal of Cancer, 77(12), 2257-2263.

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. / Bontenbal, M.; Andersson, M.; Wildiers, J.; Cocconi, G.; Jassem, J.; Paridaens, R.; Rotmensz, N.; Sylvester, R.; Mouridsen, H. T.; Klijn, J. G M; Van Oosterom, A. T.

In: British Journal of Cancer, Vol. 77, No. 12, 1998, p. 2257-2263.

Research output: Contribution to journalArticle

Bontenbal, M, Andersson, M, Wildiers, J, Cocconi, G, Jassem, J, Paridaens, R, Rotmensz, N, Sylvester, R, Mouridsen, HT, Klijn, JGM & Van Oosterom, AT 1998, 'Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer', British Journal of Cancer, vol. 77, no. 12, pp. 2257-2263.
Bontenbal M, Andersson M, Wildiers J, Cocconi G, Jassem J, Paridaens R et al. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. British Journal of Cancer. 1998;77(12):2257-2263.
Bontenbal, M. ; Andersson, M. ; Wildiers, J. ; Cocconi, G. ; Jassem, J. ; Paridaens, R. ; Rotmensz, N. ; Sylvester, R. ; Mouridsen, H. T. ; Klijn, J. G M ; Van Oosterom, A. T. / Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. In: British Journal of Cancer. 1998 ; Vol. 77, No. 12. pp. 2257-2263.
@article{4b6fc374d64548549a2b02cb1196547f,
title = "Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer",
abstract = "The EORTC Breast Cancer Cooperative Group carried out a randomized trial to compare doxorubicin with epirubicin as second-line chemotherapy in patients with metastatic breast cancer. Two hundred and fifty-nine patients with at least one site of metastatic disease entered this trial, of whom 232 patients were eligible. Treatment consisted of doxorubicin 75 mg m-2 or epirubicin 90 mg m-2 i.v. every 3 weeks. The overall response rates for doxorubicin and epirubicin were 36{\%} and 28{\%} respectively (P = 0.173). The median time to progression was 23 weeks for doxorubicin and 19 weeks for epirubicin (P = 0.063) and the median duration of response was 40 weeks for doxorubicin and 32 weeks for epirubicin (P = 0.059). The median survival was 47 weeks for doxorubicin and 44 weeks for epirubicin (P = 0.196). Leucocyte count on retreatment day (P = 0.011) and platelet nadir (P = 0.031) were significantly lower in the doxorubicin-treated group. Also mucositis (P <0.001), diarrhoea (P = 0.005) and haemorrhage (P = 0.048) were significantly worse in the doxorubicin arm. Nine patients on doxorubicin and two patients on epirubicin experienced congestive heart failure (CHF). At the dose levels used in this study, no statistical differences in response rate and survival were found between the two treatment arms. Treatment with doxorubicin tended to result in a slightly longer duration of response and time to progression but doxorubicin was more toxic than epirubicin.",
keywords = "Doxorubicin, Epirubicin, Metastatic breast cancer",
author = "M. Bontenbal and M. Andersson and J. Wildiers and G. Cocconi and J. Jassem and R. Paridaens and N. Rotmensz and R. Sylvester and Mouridsen, {H. T.} and Klijn, {J. G M} and {Van Oosterom}, {A. T.}",
year = "1998",
language = "English",
volume = "77",
pages = "2257--2263",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer

AU - Bontenbal, M.

AU - Andersson, M.

AU - Wildiers, J.

AU - Cocconi, G.

AU - Jassem, J.

AU - Paridaens, R.

AU - Rotmensz, N.

AU - Sylvester, R.

AU - Mouridsen, H. T.

AU - Klijn, J. G M

AU - Van Oosterom, A. T.

PY - 1998

Y1 - 1998

N2 - The EORTC Breast Cancer Cooperative Group carried out a randomized trial to compare doxorubicin with epirubicin as second-line chemotherapy in patients with metastatic breast cancer. Two hundred and fifty-nine patients with at least one site of metastatic disease entered this trial, of whom 232 patients were eligible. Treatment consisted of doxorubicin 75 mg m-2 or epirubicin 90 mg m-2 i.v. every 3 weeks. The overall response rates for doxorubicin and epirubicin were 36% and 28% respectively (P = 0.173). The median time to progression was 23 weeks for doxorubicin and 19 weeks for epirubicin (P = 0.063) and the median duration of response was 40 weeks for doxorubicin and 32 weeks for epirubicin (P = 0.059). The median survival was 47 weeks for doxorubicin and 44 weeks for epirubicin (P = 0.196). Leucocyte count on retreatment day (P = 0.011) and platelet nadir (P = 0.031) were significantly lower in the doxorubicin-treated group. Also mucositis (P <0.001), diarrhoea (P = 0.005) and haemorrhage (P = 0.048) were significantly worse in the doxorubicin arm. Nine patients on doxorubicin and two patients on epirubicin experienced congestive heart failure (CHF). At the dose levels used in this study, no statistical differences in response rate and survival were found between the two treatment arms. Treatment with doxorubicin tended to result in a slightly longer duration of response and time to progression but doxorubicin was more toxic than epirubicin.

AB - The EORTC Breast Cancer Cooperative Group carried out a randomized trial to compare doxorubicin with epirubicin as second-line chemotherapy in patients with metastatic breast cancer. Two hundred and fifty-nine patients with at least one site of metastatic disease entered this trial, of whom 232 patients were eligible. Treatment consisted of doxorubicin 75 mg m-2 or epirubicin 90 mg m-2 i.v. every 3 weeks. The overall response rates for doxorubicin and epirubicin were 36% and 28% respectively (P = 0.173). The median time to progression was 23 weeks for doxorubicin and 19 weeks for epirubicin (P = 0.063) and the median duration of response was 40 weeks for doxorubicin and 32 weeks for epirubicin (P = 0.059). The median survival was 47 weeks for doxorubicin and 44 weeks for epirubicin (P = 0.196). Leucocyte count on retreatment day (P = 0.011) and platelet nadir (P = 0.031) were significantly lower in the doxorubicin-treated group. Also mucositis (P <0.001), diarrhoea (P = 0.005) and haemorrhage (P = 0.048) were significantly worse in the doxorubicin arm. Nine patients on doxorubicin and two patients on epirubicin experienced congestive heart failure (CHF). At the dose levels used in this study, no statistical differences in response rate and survival were found between the two treatment arms. Treatment with doxorubicin tended to result in a slightly longer duration of response and time to progression but doxorubicin was more toxic than epirubicin.

KW - Doxorubicin

KW - Epirubicin

KW - Metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=7144228603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7144228603&partnerID=8YFLogxK

M3 - Article

C2 - 9649142

AN - SCOPUS:7144228603

VL - 77

SP - 2257

EP - 2263

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -